Core Viewpoint - Lu Kang Pharmaceutical (600789.SH) expects a significant decline in net profit for the fiscal year 2025, projecting a range of 110 million to 145 million yuan, which represents a year-on-year decrease of 63.26% to 72.13% [1] Group 1: Financial Performance - The anticipated net profit for 2025 is estimated to be between 110 million and 145 million yuan [1] - This projection indicates a substantial decrease in profitability compared to the previous year [1] Group 2: Reasons for Performance Change - The decline in profit is attributed to several factors, including the previous year's substantial asset disposal gains from the transfer of land in the southern plant area [1] - Market demand has slowed down, and price reductions due to centralized procurement have put pressure on both volume and pricing [1] - Increased amortization of research and technical assets has also contributed to the financial downturn [1]

证券之星消息，1月26日化学制药板块较上一交易日下跌0.18%，富祥药业领跌。当日上证指数报收于 4132.61，下跌0.09%。深证成指报收于14316.64，下跌0.85%。化学制药板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日化学制药板块主力资金净流入11.16亿元，游资资金净流入2.2亿元，散户资金净 流出13.37亿元。化学制药板块个股资金流向见下表： | 代码 | 名称 | 主力净流入 (元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 600789 | 鲁抗医药 | 26653 | 29.72% | -1.98亿 | -14.72% | -2.01 乙 | -14.99% | | 300723 | 一品红 | 1.00 Z | 13.23% | 2678.72万 | 3.54% | -1.27 Z | -16.76% ...

Market Overview - The Shanghai Composite Index experienced a sideways movement, while the Shenzhen Component Index and ChiNext Index fell nearly 1%. The trading volume reached 3.28 trillion yuan, with nearly 3,800 stocks declining across the Shanghai and Shenzhen markets [1] - Precious metals stocks surged, with companies like Zhongjin Gold and Western Gold hitting the daily limit. The pharmaceutical sector also saw strong performance, with stocks such as Capstone Bio and Maike Bio reaching the daily limit [1] Key Highlights Precious Metals - Gold and silver stocks saw significant gains, with multiple stocks like Silver Nonferrous and Sichuan Gold hitting the daily limit. On January 26, spot gold surged, breaking the $5,000 mark in the morning and later surpassing $5,100 per ounce, setting a new historical high [4] - Companies such as Zhongjin Gold and Western Gold reported increases of 10% and 9.99% respectively, with market capitalizations of 159.96 billion yuan and 334.91 billion yuan [6][10] Pharmaceuticals - The pharmaceutical sector experienced a notable rise, with stocks like Teva Pharmaceutical, Hualan Biological Engineering, and Luyin Pharmaceutical reaching the daily limit. The sector's performance was influenced by the recent outbreak of the Nipah virus in India, prompting increased vigilance in neighboring countries [8][9] - Teva Pharmaceutical's stock rose by 10.01%, while Hualan Biological Engineering surged by 20% [10] Cloud Computing - The cloud computing sector saw an uptick, with stocks like Hasen Co., Qunxing Toys, and Wangsu Technology hitting the daily limit. Amazon Web Services recently raised its EC2 machine learning capacity block prices by approximately 15%, indicating a significant shift in cloud computing pricing logic amid AI resource shortages [12][14] - Analysts predict that this price increase may trigger a chain reaction among cloud service providers, with domestic and international companies likely to follow suit [12][14] Other Sectors - The oil and gas sector saw a midday rally, with Zhongman Petroleum hitting the daily limit and China National Offshore Oil Corporation rising over 6% to reach a new high. However, the commercial aerospace concept experienced adjustments, with stocks like China Satellite and China Satcom hitting the daily limit [1] - The robotics and photovoltaic sectors showed mixed performance, while aerospace and semiconductor sectors faced the largest declines [14]

据世界卫生组织等机构介绍，尼帕病毒能攻击人的肺部和大脑，症状包括发烧、头疼、嗜睡、意识模糊 和昏迷，感染者的死亡率可达40%以上。这种病毒从感染到出现症状的潜伏期一般为4天至14天，最长 可达45天。目前尚无专门针对尼帕病毒的疫苗和有效疗法。 据新华社，泰国民航局宣布，1月26日起对来自印度西孟加拉邦的航班进行全面筛查，以防止尼帕病毒 输入泰国。筛查从26日0时起开始实施，同时将根据形势发展随时调整。 编辑丨瑜见 | 代码 | 名称 | 张唱 | 总金额 | 总市值 | 现价 | | --- | --- | --- | --- | --- | --- | | 300463 | 迈克生物 | +20.03% | 7666.6 | 85.86 Z | 14.20 | | 300638 | 凯普生物 | +20.03% | 3.36 Z | 46.87 G | 7.25 | | 688317 | 之江生物 | +20.01% | 3.20 乙 | 49.10 Z | 25.55 | | 301207 | 华兰疫苗 | +20.00% | 5.75 G | 140.3 Z | 23.34 | | 688670 | 金 ...

Group 1 - The flu sector experienced a significant surge on January 26, with companies such as Maike Bio, Cape Bio, Zhijiang Bio, and Hualan Vaccine hitting a 20% limit up, while others like Da'an Gene, Te Yi Pharmaceutical, and Lukan Pharmaceutical also reached their limit up [1] - Notable increases were observed in companies like Zhi Fei Bio, Wanfu Bio, CanSino, and Watson Bio, which rose over 10% [1] Group 2 - In West Bengal, India, five confirmed cases of Nipah virus infection have been reported, including healthcare workers, leading to nearly 100 individuals being asked to stay in isolation [3] - The Nipah virus can severely affect the lungs and brain, with symptoms including fever, headache, drowsiness, confusion, and coma, and a mortality rate that can exceed 40% [3] - Thailand's Civil Aviation Authority announced comprehensive screening for flights from West Bengal starting January 26 to prevent the Nipah virus from entering the country, with adjustments to be made based on the evolving situation [3]

Group 1 - The core point of the article is that LuKang Pharmaceutical announced the use of idle raised funds to temporarily supplement its working capital [2] - The company will utilize 200 million yuan of temporarily idle raised funds for this purpose [2] - The approval for this decision was made during the 12th (temporary) meeting of the 11th Board of Directors held on January 23, 2026 [2] Group 2 - The duration for using the funds is set to be no more than 12 months from the date of the board's approval [2]

Core Viewpoint - The company, LuKang Pharmaceutical, has announced a plan to utilize part of its idle raised funds for cash management, ensuring that it does not affect the normal operation of investment projects [2] Group 1: Company Announcement - On January 23, 2026, LuKang Pharmaceutical held the twelfth (temporary) meeting of the eleventh board of directors to approve the proposal for cash management using idle raised funds [2] - The company will use an amount not exceeding RMB 31 million for cash management, with a validity period of 12 months from the date of board approval [2] - A dedicated settlement account for cash management products has been opened at the Jining Jin Yu Road Branch of China Postal Savings Bank [2]

Group 1 - The company LuKang Pharmaceutical held its 12th temporary board meeting on January 23, 2026, to discuss the proposal regarding the use of raised funds to replace previously invested self-raised funds [1] - The meeting was conducted in a hybrid format, combining in-person and communication methods [1] Group 2 - Local state-owned assets have begun purchasing foreclosed properties, acquiring over 60 units in the Nansha District of Guangzhou at prices around 6,000 to 7,000 yuan per unit, while the average listing price for second-hand homes in the same community exceeds 20,000 yuan [1]

中国国际金融股份有限公司 关于山东鲁抗医药股份有限公司 使用部分闲置募集资金临时补充流动资金的核查意见 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为山东鲁抗医 药股份有限公司（以下简称"鲁抗医药"或"公司"）的保荐机构，根据《证券发行上市保 荐业务管理办法》《上市公司募集资金监管规则》《上海证券交易所股票上市规则》《上 海证券交易所上市公司自律监管指引第 1 号——规范运作》等有关法律、行政法规、部 门规章及业务规则的要求，对鲁抗医药本次使用暂时闲置募集资金临时补充流动资金的 相关事项进行了认真、审慎核查，具体情况如下： 一、募集资金基本情况 | 发行名称 | 2024 年向特定对象发行股票 | | | | | --- | --- | --- | --- | --- | | 募集资金总额 | 119,999.999574 | | | 万元 | | 募集资金净额 | 118,682.913868 | | | 万元 | | 募集资金到账时间 | 年 月 2025 | 12 | 15 | 日 | | 前次用于暂时补充流动资金的募集资金归还日期及金额 | 不适用 | | | | 二、募集资金投资 ...

关于山东鲁抗医药股份有限公司 以募集资金置换预先投入募投项目的 自筹资金的专项签证报告 | | | 二、山东鲁抗医药股份有限公司关于以募集资金置换预先投 3-4 入募投项目的自筹资金的专项说明 和信会计师事务所 (特殊普通合伙) 二〇二六年一月二十三日 以募集资金置换预先投入墓授项目的自筹资金的专项鉴证报告 关于山东鲁抗医药股份有限公司 以募集资金置换预先投入募投项目的 自筹资金的专项鉴证报告 和信专字(2026)第 000003 号 山东鲁抗医药股份有限公司全体股东: 我们接受委托,对后附的山东鲁抗医药股份有限公司(以下简称"鲁抗医药 公司"）管理层编制的截至2026年1月22日的《山东鲁抗医药股份有限公司关于以 募集资金置换预先投入募投项目的自筹资金的专项说明》(以下简称"专项说明") 进行专项审核。 一、管理层的责任 按照《上市公司募集资金监管规则》及《上海证券交易所上市公司自律监管 指引第1号-- 规范运作》等文件的规定编制专项说明是鲁抗医药公司管理层的责 任。这种责任包括提供真实、合法、完整的鉴证材料,设计、实施和维护与专项 说明编制相关的内部控制,保证专项说明的内容真实、准确和完整,不存在虚假 记 ...